TipRanks
Advertisement
Advertisement

DE:RGN Stock Latest News

Private Markets: Varda Space, GMI headline week’s startup fundraising
The FlyPrivate Markets: Varda Space, GMI headline week’s startup fundraising
4d ago
CAT
DHR
Repligen price target raised to $225 from $175 at Barclays
PremiumThe Fly
Repligen price target raised to $225 from $175 at Barclays
5d ago
RGEN
Repligen Completes BioLife Acquisition to Expand Cell Therapies
PremiumCompany Announcements
Repligen Completes BioLife Acquisition to Expand Cell Therapies
6d ago
8K
RGEN
Freshworks to replace BioLife Solutions in S&P 600 at open on 10/8
PremiumThe Fly
Freshworks to replace BioLife Solutions in S&P 600 at open on 10/8
7d ago
BLFS
FRSH
Repligen Buy Rating Reiterated as Analyst Sees Medium-Term Growth Catalysts; Price Target Maintained at $225
PremiumRatings
Repligen Buy Rating Reiterated as Analyst Sees Medium-Term Growth Catalysts; Price Target Maintained at $225
13d ago
RGEN
Repligen announces long-serving director Karen Dawes’ retirement
PremiumCompany AnnouncementsRepligen announces long-serving director Karen Dawes’ retirement
27d ago
8K
RGEN
Repligen assumed with a Buy at UBS
Premium
The Fly
Repligen assumed with a Buy at UBS
1M ago
RGEN
Repligen clears antitrust hurdle in BioLife Solutions acquisition
Premium
Company Announcements
Repligen clears antitrust hurdle in BioLife Solutions acquisition
1M ago
8K
RGEN
Stifel sees Moderna data as positive for Repligen, Maravai
PremiumThe Fly
Stifel sees Moderna data as positive for Repligen, Maravai
2M ago
MRNA
MRVI
Wells sees Repligen among key beneficiaries of Moderna’s cancer vaccine data
PremiumThe Fly
Wells sees Repligen among key beneficiaries of Moderna’s cancer vaccine data
2M ago
DHR
MRK
Repligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns
PremiumCompany Announcements
Repligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns
2M ago
RGEN
Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target
PremiumRatings
Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target
2M ago
RGEN
Repligen price target raised to $175 from $165 at JPMorgan
PremiumThe FlyRepligen price target raised to $175 from $165 at JPMorgan
2M ago
RGEN
Repligen rises 15.4%
Premium
The Fly
Repligen rises 15.4%
3M ago
RGEN
Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength
Premium
Ratings
Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength
3M ago
RGEN
Repligen rises 16.2%
PremiumThe Fly
Repligen rises 16.2%
3M ago
RGEN
Repligen reports Q2 adjusted EPS 54c, consensus 45c
PremiumThe Fly
Repligen reports Q2 adjusted EPS 54c, consensus 45c
3M ago
RGEN
Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00
PremiumThe Fly
Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00
3M ago
RGEN
RGEN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RGEN Upcoming Earnings Report: What to Expect?
3M ago
RGEN
Midday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
PremiumThe FlyMidday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
3M ago
T
PM
BioLife Solutions downgraded to Hold from Buy at Lake Street
Premium
The Fly
BioLife Solutions downgraded to Hold from Buy at Lake Street
3M ago
BLFS
RGEN
Repligen to Acquire BioLife, Expanding Cell Therapy Reach
Premium
Company Announcements
Repligen to Acquire BioLife, Expanding Cell Therapy Reach
3M ago
8K
RGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >